Machine learning and memory loss
this, researchers need to focus on developing more interpretable models, perhaps by combining complex algorithms with simpler, rule-based systems as suggested in Kording’s book, or create better visual explanation tools showing how decisions are made (note 4).
The challenges extend beyond just model interpretability to implementation gaps in real healthcare settings. As Rajpurkar et al. notes, many ML models are tested under ideal research conditions using high-quality brain scans from well-equipped academic hospitals (note 2). However, the National Institute on Ageing points out that in clinics with limited resources or developing regions, the same technology might fail because of poorer quality imaging equipment or different patient populations. 8 This means ML tools must be designed for diverse clinical environments from the outset. 9 Researchers should involve a broader range of hospitals, including those in underserved areas, during the development phase to ensure these technologies can benefit all patients, not just those at elite medical centres. The Lancelot Neurology's review further emphasizes that without such inclusive development, even the most advanced ML solutions can worsen healthcare inequalities rather than improving them (note 6). Although ML offers progressive possibilities for treating memory loss, there are still challenges to overcome. Issues like the risks of BCIS, the difficulty of understanding how ML models work, and the gap between research labs and hospitals must be addressed. These problems, including concerns about fairness, privacy and practical use, will need attention as technology develops. While ML offers transformative potential for treating memory loss, it also presents challenges and ethical dilemmas. Obermeyer’s research demonstrates the risk of bias in AI models, where datasets skewed toward demographics may lead to inaccurate predictions for underrepresented groups (note 7). For instance, if a model is trained primarily on data from younger patients, its effectiveness for elderly populations (the primary demographic affected by Alzheimer's) could be compromised. This raises questions about fairness and the need for diverse, inclusive datasets. Privacy is another critical concern. Brain data is highly sensitive, and its misuse could have severe consequences, such as discrimination by insurers or employers based on predicted cognitive decline. Independent analysis suggests that current regulations may lag technological advancements, requiring stricter protocols for data anonymization and consent. Beyond these issues, there is a philosophical tension between AI driven diagnostics and human judgment. Over- reliance on algorithms might lead to ‘black-box’ decisions where the reasoning behind a diagnosis
8 See National Institute on Aging. ‘Artificial Intelligence and Alzheimer's Research.’ 2022. Accessed July 7, 2025. https://www.nia.nih.gov/news/artificial-intelligence-and-alzheimers-research. 9 See Woo, C-W. et al. 2017. ‘Building Better Biomarkers: Brain Models in Translational Neurology.’
Neuron 96, no. 2 (2017). Accessed July 12, 2025. https://www.cell.com/neuron/fulltext/S0896-
6273(17)30842-4.
109
Made with FlippingBook - PDF hosting